Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alkermes, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a diagnosis of chronic schizophrenia or schizoaffective disorder
Has demonstrated ability to tolerate aripiprazole
Has been on a stable antipsychotic medication regimen without any changes for at least 2 months prior to screening
Has a body mass index (BMI) of 18.0 to 40.0 kg/m2, inclusive
Additional criteria may apply
You may not be if
Is pregnant, is planning to become pregnant, or is currently breastfeeding
Has received aripiprazole lauroxil or IM depot aripiprazole within 6 months, or other long-acting, injectable antipsychotic medication within 3 months or currently treated with clozapine
Is a danger to himself/herself at screening or upon admission
Has a history of or positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Has a positive urine drug screen at screening or Day 1
Additional criteria may apply
Clareo Health | A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
